Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11053280-B2
Application number	US-202016996007-A
Country	US
Kind code	B2
Filing date	Aug 18, 2020
Priority date	Dec 6, 2019
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

First claim

What is claimed is:

1. A method of producing aflibercept, comprising:
(a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM);
(b) binding aflibercept from said clarified harvest to a Protein A resin, wherein said aflibercept includes variants that have at least one oxidized amino acid residue selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
(c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said eluate has a first color;
(d) subjecting said eluate comprising aflibercept to an anion exchange chromatography (AEX) column; and
(e) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color of said affinity eluate is a more intense yellow brown color than said second color of said flowthrough fraction when said affinity eluate and flowthrough fraction protein concentrations are normalized.

2. The method of claim 1 , wherein said cells are selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

3. The method of claim 1 , wherein said oxidized amino acid residue is histidine.

4. The method of claim 1 , wherein said oxidized amino acid residue is tryptophan.

5. A method of producing aflibercept from a clarified harvest of a cell cultured in a chemically defined medium (CDM), comprising:
(a) binding aflibercept from said clarified harvest to a Protein A resin;
(b) eluting said aflibercept of step (a) forming an affinity eluate, wherein said eluate comprises acidic species of aflibercept;
(c) subjecting said eluted aflibercept to an anion exchange (AEX) chromatography column; and
(d) collecting one or more flowthrough fractions, and wherein the percent of acidic species of aflibercept in said affinity eluate of step (b) is greater than the percent of acidic species of aflibercept in said one or more flowthrough fractions of (d) when the concentrations of protein in said affinity eluate and flowthrough fractions are normalized to 10.0 g/L, and
wherein said acidic species of aflibercept correspond to peaks that elute earlier than a main peak in a cation exchange chromatography (CEX) chromatogram of aflibercept, and wherein the chromatogram is generated using a first mobile phase of 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.7 and a second mobile phase of 40 mM sodium phosphate, 100 mM sodium chloride, pH 9.0 (mobile phase B), and wherein the chromatogram is generated using detection at 280 nm.

6. The method of claim 5 , wherein said acidic species of aflibercept comprises aflibercept having at least one oxidized amino acid residue selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

7. The method of claim 5 , further comprising after binding aflibercept from said clarified harvest, subjecting aflibercept to one or more further chromatographic steps selected from the group consisting of: cation exchange chromatography (CEX), hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

8. The method of claim 5 , wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

9. The method of claim 6 , wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

10. The method of claim 6 , wherein said acidic species of aflibercept comprises aflibercept having at least one oxidized amino acid residue of tryptophan.

11. The method of claim 6 , wherein said acidic species of aflibercept comprises aflibercept having at least one oxidized amino acid residue of histidine.

Assignees

• Regeneron Pharma

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha
• Wang Shunhai
• Li Ning

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title